ReviewCNS drugs2009
Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 122 citations in OpenAlex.
- Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ.Nature communications · 2026Article
- Adjunctive Endoxifen in a Middle-aged Man with Persistent Manic Symptoms Despite Standard Antimanic Agents: A Case Report of Early Clinical Response.Indian journal of psychological medicine · 2026Article
- The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series.Indian journal of psychological medicine · 2024Article
- New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacological reviews · 2024Review
- An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.International journal of molecular sciences · 2023Review
- Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.Frontiers in neuroscience · 2023Review
- A critical evaluation of dynamical systems models of bipolar disorder.Translational psychiatry · 2022Review
- Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview.Cellular and molecular neurobiology · 2022Review
- Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms.Case reports in psychiatry · 2022Article
- The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder.Psychiatry and clinical psychopharmacology · 2021Article
- Article
- Intracellular Signaling Cascades in Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- Neuropsychiatric effects of tamoxifen: Challenges and opportunities.Frontiers in neuroendocrinology · 2020Review
- The role of prelimbic and anterior cingulate cortices in fear memory reconsolidation and persistence depends on the memory age.Learning & memory (Cold Spring Harbor, N.Y.) · 2020Article
- A Novel CosegregatingGenes · 2020Article
- The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer’s Disease-Induced Cognitive DysfunctionIranian biomedical journal · 2020Review
- Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization.Scientific reports · 2019Article
- Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation.Molecular neurobiology · 2019Review
- Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic CaJournal of molecular and cellular cardiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.